4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 57 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $83,000 | +40.7% | 6,485 | +101.2% | 0.00% | – |
| Q2 2023 | $59,000 | +96.7% | 3,223 | +84.8% | 0.00% | – |
| Q1 2023 | $30,000 | -61.5% | 1,744 | -49.8% | 0.00% | – |
| Q4 2022 | $78,000 | +2500.0% | 3,471 | +697.9% | 0.00% | – |
| Q3 2022 | $3,000 | +200.0% | 435 | +108.1% | 0.00% | – |
| Q2 2022 | $1,000 | -96.3% | 209 | -88.1% | 0.00% | – |
| Q1 2022 | $27,000 | -77.1% | 1,756 | -67.4% | 0.00% | – |
| Q4 2021 | $118,000 | +87.3% | 5,382 | +129.6% | 0.00% | – |
| Q3 2021 | $63,000 | +293.8% | 2,344 | +247.3% | 0.00% | – |
| Q2 2021 | $16,000 | -48.4% | 675 | -5.3% | 0.00% | – |
| Q1 2021 | $31,000 | – | 713 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 3,000,000 | $38,190,000 | 4.02% |
| Casdin Capital, LLC | 1,033,811 | $13,160,414 | 1.46% |
| BVF INC/IL | 4,007,413 | $51,014,367 | 1.38% |
| Deep Track Capital, LP | 2,778,107 | $35,365,302 | 1.36% |
| Opaleye Management Inc. | 308,500 | $3,927,205 | 1.28% |
| Eagle Health Investments LP | 437,911 | $5,574,607 | 1.23% |
| Novo Holdings A/S | 1,200,000 | $15,276,000 | 1.13% |
| RA Capital Management | 4,163,211 | $52,997,676 | 1.04% |
| VIKING GLOBAL INVESTORS LP | 4,787,914 | $60,950,145 | 0.25% |
| HighVista Strategies LLC | 33,419 | $425,424 | 0.20% |